市场调查报告书
商品编码
1308576
到 2030 年超声心动图(心臟超声设备)市场预测:按类型、设备展示、技术、最终用户和地区进行的全球分析Echocardiography Market Forecasts to 2030 - Global Analysis By Type, Device Display (CCD Colour Display and Black & White Display), Technology, End User and By Geography |
根据Stratistics MRC 的数据,2023 年全球超声心动图(心臟超声机)市场规模将达到19 亿美元,预测期内復合年增长率为9.5%,到2030 年将达到35 %。预计将达到1亿美元。
超声心动图通常称为迴声或心臟超声机,使用声波创建心臟图像以查找心血管疾病。 该工具可用于查找血块、检查心室和瓣膜。 经胸超声心动图、经食管超声心动图和负荷超声心动图是三种不同的心臟超声机器,可用于各种诊断程序。 由于其非侵入性,经胸超声心动图是识别心臟问题最常用的诊断程序。
根据英国心臟基金会 2022 年发布的数据,英国约有 15 亿人被诊断患有房颤。
心脏病患病率的上升增加了对微创心臟手术的需求。 此外,结合ICE和其他成像方式的集成系统的开发以及超声心动图系统的技术发展(例如图像质量的提高)预计将进一步促进市场扩张。 由于疼痛更轻、住院时间更短、恢復更快,微创心臟手术的需求也很高。 这些手术通常使用超声心动图来引导导管和其他装置插入心臟。
使用超声心动图需要专门的培训和专业知识。 缺乏能够操作这些系统的熟练专业人员可能会限制部署。 此外,还有其他成像技术,例如经食管超声心动图(TEE)和磁共振成像(MRI),它们可能会与超声心动图争夺市场份额。
在超声心动图市场,人们对便携式超声检查的兴趣与日俱增。 诊断性放射性核素心动图与超声心动图面临着重大的竞争挑战。 然而,脉衝多普勒的改进使得将可靠的探针植入食道并提高心臟成像的分辨率成为可能。 超声心动图行业的公司在声学量化方法的研发 (R&D) 上投入了大量资金,这些方法有助于识别和跟踪心肌内缘和血池相交的线,使超声心动图成为医生的首选。到
便携式心臟超声机有一些局限性。 儘管尺寸很小,但屏幕很小并且会影响诊断。 由于超声频率低,分辨率低,图像优化不佳。 此外,有时仅提供 2D 图像。 因此,这些设备体积庞大且价格昂贵,因此它们可能在未来几年内不会流行。
在新冠肺炎 (COVID-19) 疫情期间,市场增长放缓。 下降的原因是前往诊所和医院诊断和治疗心血管疾病的患者减少以及非紧急手术的推迟。 2020年全球市场同比下降8.3%。 在此期间,非 COVID-19 相关的诊断程序被认为是低优先级,导致心血管疾病检测显着减少。
心内超声心动图部分是一种称为心内超声心动图(ICE) 的医学成像程序,它使用插入心臟的小型超声探头来生成心室、瓣膜和静脉的图像。因此,预计会有良好的增长。 心脏病发病率的增加、对微创心臟手术的需求以及改进的 ICE 系统技术带来了更高的准确性和利用率,推动了这一市场的发展。
预计 3D 和 4D 细分市场在预测期内的复合年增长率最高。 该技术卓越的图像质量、逼真的解剖图像、体积测量能力以及识别间隔异常的能力促进了这一领域的增长。
由于新产品和创新产品的广泛接受、对各种可用医疗程序的了解以及支持医疗程序的强大基础设施投资,北美将在预测期内继续增长。预计将占据最大的市场份额在 推动该地区市场的其他重要因素包括政府对医疗基础设施和超声心动图研究与开发的有利支持。
预计亚太地区在预测期内的复合年增长率最高。 这是由于印度和中国有大量人口受到心血管疾病的影响,以及亚太地区存在未开发的潜力和人们对医疗状况的认识不断提高,从而促进了市场的增长。 由于吸烟、超重和血糖水平升高等生活方式因素,南亚、印度、中国和澳大利亚患心血管疾病的风险很高。
2022年9月,三星电子有限公司宣布推出V7超声系统。 该系统具有 AutoIMT 工具,用于分析患者潜在的心血管疾病风险。
2022 年 3 月,Koninklijke Philips N.V. 在美国心脏病学会年度科学会议暨博览会 (ACC 2022) 上宣布推出超声工作区。
2022 年 2 月,Koninklijke Philips N.V. 在其 Lumify 手持式超声系统中添加了脉衝多普勒技术。 此次更新旨在扩展设备的血流动力学评估和测量功能。
According to Stratistics MRC, the Global Echocardiography Market is accounted for $1.9 billion in 2023 and is expected to reach $3.5 billion by 2030 growing at a CAGR of 9.5% during the forecast period. Echocardiography, commonly known as an echo or cardiac ultrasound, creates images of the heart using sound waves in order to look for any cardiovascular illness. With the use of this tool, blood clots may be found and the chambers and valves of the heart can be studied. Transthoracic, transesophageal, and stress cardiac ultrasonography are three different cardiac ultrasound examinations that are utilised for various diagnostic procedures. Due to its non-invasive nature, transthoracic cardiac ultrasonography is the most often utilised diagnostic procedure for identifying heart problems.
According to the British Heart Foundation data published in 2022, around 1.5 billion people in the U.K. have been diagnosed with atrial fibrillation.
The rising incidence of heart disease and the rising demand for less invasive cardiac operations. Additionally, the development of integrated systems that combine ICE with other imaging modalities and technological developments in echocardiography systems, such as enhanced picture quality, are anticipated to further propel market expansion. Additionally there is an increasing demand for minimally invasive cardiac operations since they are less painful, require fewer hospital stays, and have quicker recovery times. During these surgeries, echocardiography is frequently utilised as a guide for inserting catheters and other devices into the heart.
The use of echocardiography requires specialized training and expertise. The shortage of skilled professionals who can operate these systems may limit its adoption. Moreover there are alternative imaging techniques, such as transesophageal echocardiography (TEE) and magnetic resonance imaging (MRI), which may compete with echocardiography for market share.
The market for echocardiography is seeing an increase in interest in the idea of portable ultrasound. Nuclear cardiology for diagnostic purposes faces a significant competitive challenge from echocardiography. However, improvements in pulse doppler are making it possible to implant trustworthy probes into the oesophagus to increase the resolution of cardiac imaging. Companies in the echocardiography industry are investing more in research and development (R&D) for acoustic quantification methods that aid in identifying and keeping track of the line where the inner margin of the myocardium and blood pool meets is encouraging the doctors to much prefer echocardiography.
Portable cardiac ultrasonography equipment has several restrictions. Despite being smaller in size, they have a smaller screen, which may affect the diagnosis. With fewer ultrasonic frequencies, the resolution is poorer, and the image optimisation is subpar. Additionally, they may only use 2D pictures. As a result, the bulk and expensive price of these gadgets may prevent widespread use in the years to come.
During COVID-19, the market experienced a decline in its growth. Fewer patients visiting the clinics and hospitals for cardiovascular disease diagnosis and treatment and the postponement of non-emergency procedures were responsible for the decline. The global market experienced a decline of 8.3% in 2020 as compared to the past year. During this period, non-COVID-19-related diagnostic procedures were considered low-priority, which caused a significant decrease in the testing volume of cardiovascular disorders.
The Intracardiac Echocardiography segment is estimated to have a lucrative growth, due to the use of a tiny ultrasonic probe that is put within the heart, a medical imaging procedure known as intracardiac echocardiography (ICE) can produce pictures of the heart's chambers, valves, and blood veins. The market is fuelled by reasons such the increased incidence of heart illness, the need for less invasive cardiac operations, and improvements in ICE system technology that increase its accuracy and use.
The 3D & 4D (Three-Dimensional Echocardiography & 4DEchocardiography) segment is anticipated to witness the highest CAGR growth during the forecast period, due to The characteristics of this technology, including as good picture quality, realistic anatomical images, the capacity to offer volume measurement, and the ability to see septal abnormalities, have contributed to the segment's rise.
North America is projected to hold the largest market share during the forecast period owing to widespread acceptance of new and innovative goods, great knowledge of the range of medical treatments available, and major infrastructure investment supporting medical treatments. Other significant drivers propelling the market in the area include favourable government assistance for healthcare infrastructure and research and development of echocardiography.
Asia Pacific is projected to have the highest CAGR over the forecast period, owing to the vast population suffering from cardiovascular illnesses in India and China, combined with the presence of unexplored potential and increased awareness of medical conditions in Asia Pacific, all contribute to the market's growth. Due to lifestyle factors including smoking, excessive weight, and elevated blood sugar levels, the risk of cardiovascular disease is higher in South Asia, India, China, and Australia.
Some of the key players profiled in the Echocardiography Market include Siemens Healthcare GmbH, Conavi Medical, Boston Scientific Corporation, Abbott Laboratories, Koninklijke Philips NV, Goodman USA, Inc, Shifamed LLC (NuVera Medical), Johnson & Johnson Services Inc., Stereotaxis Inc., GE Healthcare, B. Braun Melsungen AG, FUJIFILM Holdings Corporation, SAMSUNG ELECTRONICS Co., Ltd, ESAOTE SPA, Meditronic, Terumo Corporation and St. Jude Medical
In September 2022, Samsung Electronics Co., Ltd. announced the launch of V7 ultrasound system. The system possesses AutoIMT tool for analyzing a patient's potential risk for cardiovascular disease.
In March 2022, Koninklijke Philips N.V. announced the launch of Ultrasound Workspace at the American College of Cardiology's Annual Scientific Session & Expo (ACC 2022).
In February 2022, Koninklijke Philips N.V. added Pulse Wave Doppler technology to Lumify, a handheld ultrasound device. The update aims to expand the hemodynamic assessment and measurement capabilities of the system.